OR WAIT null SECS
Quicker approval of new drugs by the U.S. Food and Drug Administration (FDA) has not increased the number of prescription drugs withdrawn for safety reasons in this country, according to an analysis recently completed by the Tufts Center for the Study of Drug Development.
BOSTON – Sept. 7, 2005 – Quicker approval of new drugs by the U.S. Food and Drug Administration (FDA) has not increased the number of prescription drugs withdrawn for safety reasons in this country, according to an analysis recently completed by the Tufts Center for the Study of Drug Development.
The study, highlights of which were released today, failed to establish a link between FDA approval times and drug safety, said Tufts CSDD Director Kenneth I Kaitin.
"Given rising public concern over drug safety, and assertions by FDA critics that drug safety in the U.S. has deteriorated since the adoption of user fees in 1993, we wanted to investigate the matter," he said.
"To date we have found no evidence that links the rate of drug safety withdrawals and the passage of legislation more than a dozen years ago aimed at speeding new drug approvals. In fact, since 2000 the rate of safety withdrawals in the U.S. has dropped."
Passed in 1992, the Prescription Drug User Fee Act (PDUFA) authorized the FDA to collect fees from drug companies to be used, in part, to hire additional reviewers and improve the drug review process. PDUFA was reauthorized in 1997 and again in 2002.
According to Tufts CSDD, 3.2% of all the drugs approved for sale in the U.S. in the 1980s were subsequently withdrawn. That rate increased slightly to 3.5% during the 1990s, and since then has dropped to 1.6%.
"Many factors influence drug safety, and while the vast majority of prescription drugs for sale in the U.S. offer demonstrable benefits over the risk of using that drug, it's important to understand if any aspects of the regulatory and approval process contribute to an imbalance in the benefit to risk ratio," Kaitin said. "We'll continue to study, as part of our ongoing analyses on drug safety and the regulatory review process, the effects of PDUFA on new drug development."
The Tufts CSDD analysis, summarized in the September/October Tufts CSDD Impact Report, also found that:
About the Tufts Center for the Study of Drug Development
The Tufts Center for the Study of Drug Development (http://csdd.tufts.edu) at Tufts University provides strategic information to help drug developers, regulators, and policy makers improve the quality and efficiency of pharmaceutical development, review, and utilization. Tufts CSDD, based in Boston, conducts a wide range of in-depth analyses on pharmaceutical issues and hosts symposia, workshops, and public forums on related topics, and publishes the Tufts CSDD Impact Report, a bi-monthly newsletter providing analysis and insight into critical drug development issues.